Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764276
Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Gynecologic SurgeryNational Taiwan University HospitalRecruitingNot Applicable
NCT07764276Recruiting
Not Applicable
Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Gynecologic Surger...National Taiwan Universit...
NCT07763275
Autologous Nanofat for Treatment of Atrophic ScarsBenha UniversityCompletedNot Applicable
NCT07763275Completed
Not Applicable
Autologous Nanofat for Treatment of Atrophic ScarsBenha University
NCT07762378
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic TherapyInstituto de Investigación Sanitaria Gregorio MarañónNot Yet RecruitingNot Applicable
NCT07762378Not Yet Recruiting
Not Applicable
Clinical Impact of a Machine Learning Decision Support System for Empirical Anti...Instituto de Investigació...
NCT07763067
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young Autistic ChildrenHerguner Therapy Private ClinicCompletedNot Applicable
NCT07763067Completed
Not Applicable
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young A...Herguner Therapy Private...
NCT07762508
A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low-Performance or High-Comorbidity AML Patients in CR1The First Affiliated Hospital of Soochow UniversityNot Yet RecruitingNot Applicable
NCT07762508Not Yet Recruiting
Not Applicable
A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low...The First Affiliated Hosp...
NCT07763457
Japanese Strabismus Outcomes Assessment and Research Group StudyKyoto University, Graduate School of MedicineNot Yet Recruiting
NCT07763457Not Yet Recruiting
—
Japanese Strabismus Outcomes Assessment and Research Group StudyKyoto University, Graduat...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07763587
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineNot Yet RecruitingNot Applicable
NCT07763587Not Yet Recruiting
Not Applicable
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Ben...First Teaching Hospital o...
NCT07763418
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionBristol-Myers SquibbNot Yet RecruitingPhase 1
NCT07763418Not Yet Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participan...Bristol-Myers Squibb
NCT07763639
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid TumorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.Not Yet RecruitingPhase 1
NCT07763639Not Yet Recruiting
Phase 1
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck...Baili-Bio (Chengdu) Pharm...
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07762625
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes MellitusCentral South UniversityNot Yet RecruitingNot Applicable
NCT07762625Not Yet Recruiting
Not Applicable
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestationa...Central South University
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07762729
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up StudyChildren's Hospital of Fudan UniversityEnrolling By Invitation
NCT07762729Enrolling By Invitation
—
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up...Children's Hospital of Fu...
NCT07762482
Periodontal Tissue Stability After Surgical Correction of Altered Passive EruptionUniversity of Sao PauloRecruitingNot Applicable
NCT07762482Recruiting
Not Applicable
Periodontal Tissue Stability After Surgical Correction of Altered Passive Erupti...University of Sao Paulo
NCT07762495
Echocardiographic Molecular Imaging for POC Detection of IschemiaNational Heart, Lung, and Blood Institute (NHLBI)Not Yet RecruitingEarly Phase 1
NCT07762495Not Yet Recruiting
Early Phase 1
Echocardiographic Molecular Imaging for POC Detection of IschemiaNational Heart, Lung, and...
NCT07763964
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763964Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07763899
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763899Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
Result Breakdown
Not yet recruiting10 (50%)
Completed5 (25%)
Recruiting4 (20%)
Enrolling by invitation1 (5%)
not_applicable11 (55%)
Not Specified4 (20%)
Phase 13 (15%)
Phase 41 (5%)
Early Phase 11 (5%)